292 filings
Page 6 of 15
8-K
6p1tefub37aqg5qhtn4q
1 Mar 21
Axsome Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
7:28am
8-K
jk59b3 3qw
24 Feb 21
Other Events
5:17pm
8-K
142ufa7q3der9zp
28 Jan 21
Regulation FD Disclosure
7:55am
8-K
1tst7y pwbc
31 Dec 20
Other Events
7:06am
8-K
6b6jjc fr86m3z3r1x5l
8 Dec 20
Other Events
7:07am
8-K
u3ove
2 Dec 20
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
7:17am
8-K
obzow2
1 Dec 20
Other Events
7:01am
8-K
vsmrz sy34fi
5 Nov 20
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
5:11pm
8-K
6ot2m q45
29 Sep 20
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
7:06am
8-K
45jdura 3auz5ezm
24 Sep 20
Other Events
7:06am
8-K/A
oe9w un063k
22 Sep 20
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
12:00am
8-K
dxil p87w
21 Sep 20
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
7:10am
8-K
aaatrt6
16 Sep 20
Other Events
7:08am
8-K
evaz4
14 Sep 20
Other Events
7:05am
8-K
0368y89n
8 Sep 20
Departure of Directors or Certain Officers
4:39pm
8-K
pkjb31fvnma3kvm0 uf
31 Aug 20
Initiation of Phase 3, placebo-controlled, randomized-withdrawal efficacy trial on track for 4Q 2020
8:17am
8-K
yr0mfh3
20 Aug 20
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
8:25am